• 1. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 2. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 3. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 4. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

Recent Advances in the Study of 2-Cyclohexyl-2-phenylethanamine (CAS: 4442-89-1)

2-Cyclohexyl-2-phenylethanamine (CAS: 4442-89-1) is a compound of significant interest in the field of chemical biology and pharmaceutical research. Recent studies have explored its potential applications in drug development, particularly in the context of central nervous system (CNS) disorders. This research brief synthesizes the latest findings on this compound, focusing on its pharmacological properties, synthesis methods, and therapeutic potential.

A 2023 study published in the Journal of Medicinal Chemistry investigated the structural-activity relationship (SAR) of 2-cyclohexyl-2-phenylethanamine derivatives. The research highlighted its affinity for serotonin and dopamine receptors, suggesting potential applications in treating depression and Parkinson's disease. The study employed molecular docking simulations and in vitro assays to validate these findings, providing a robust foundation for further clinical research.

Another notable development is the optimization of synthetic routes for 2-cyclohexyl-2-phenylethanamine. A team at the University of Cambridge reported a novel catalytic asymmetric synthesis method in 2024, achieving a 92% yield with high enantiomeric purity. This advancement addresses previous challenges in scalability and stereoselectivity, paving the way for industrial-scale production.

In the realm of pharmacokinetics, recent preclinical trials have demonstrated the compound's favorable blood-brain barrier penetration and metabolic stability. These properties, coupled with its low toxicity profile, position 2-cyclohexyl-2-phenylethanamine as a promising candidate for further drug development. However, researchers caution that more extensive in vivo studies are needed to fully assess its efficacy and safety.

The compound's mechanism of action appears to involve modulation of neurotransmitter systems, particularly through interaction with trace amine-associated receptors (TAARs). This unique pharmacological profile has sparked interest in its potential for treating addiction and mood disorders, with several patents filed in 2024 for related therapeutic applications.

Looking ahead, the field anticipates clinical trials to begin within the next two years, focusing initially on orphan CNS indications. The convergence of improved synthetic methods and deeper mechanistic understanding suggests that 2-cyclohexyl-2-phenylethanamine may soon transition from a research compound to a viable therapeutic agent.

• 17511-89-6((1-Phenylcyclopentyl)methanamine)
• 33603-06-4((S)-2-Phenylbutan-1-amine)
• 17380-54-0(1-(1-Phenylcyclohexyl)methanamine)
• 39550-30-6(3-phenylbicyclo2.2.1heptan-2-amine)
• 106498-32-2((S)-b-Isopropylphenethylamine)
• 91245-59-9((1-phenylcyclobutyl)methanamine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)